ABSTRACT
Teduglutide, a dipeptidylpeptidase degradation-resistant glucagon-like peptide-2 analog, has been shown to enhance structural and functional intestinal adaptation in humans and increase fluid absorption in patients with short bowel syndrome (SBS).
